Tarsus Pharmaceuticals, Inc.
TARSHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tarsus Pharmaceuticals, Inc. focuses on Biotechnology services and products. Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. At a $3.98B market cap, Tarsus Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Market Cap
$3.98B
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
39.05
EPS (TTM)
$-1.07
EPS (Fwd)
$2.33
ROE
-13.7%
ROA
-5.5%
Cash
$449.7M
Total Debt
$88.8M
Free CF
$67.5M
52W Change
59.6%
Annual Financials
Cash vs Debt
Where TARS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TARS finished 26.24% above its 150-day moving average ($65.56) and 20.64% above its 200-day moving average ($68.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TARS overbought or oversold?
At the September 3, 2026 close, TARS's RSI(14) was 80.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tarsus Pharmaceuticals, Inc. holds $449.7M in cash against $88.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $67.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -13.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $25.8M (2022) to $451.4M (2025), reflecting a 1648% increase over the period.
TARS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing TARS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.